PHASE I STUDY OF OMBRABULIN IN COMBINATION WITH CISPLATIN (CDDP) ADMINISTERED EVERY 3 WEEKS TO JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS

被引：0
|
作者：
Takahashi, S.
Ura, T. [1 ]
Nakano, K.
Chin, K.
Yokoyama, M.
Hatake, K.
Yokota, T. [1 ]
Shitara, K. [1 ]
Muro, K. [1 ]
Aoyama, T.
机构：
[1] Aichi Canc Ctr Hosp, Dept Clin Oncol, Aichi, Japan
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：110 / 110
页数：1
相关论文
共 50 条
  • [1] Phase 1 study of ombrabulin in combination with cisplatin (CDDP) in Japanese patients with advanced solid tumors
    Takahashi, Shunji
    Nakano, Kenji
    Yokota, Tomoya
    Shitara, Kohei
    Muro, Kei
    Sunaga, Yoshinori
    Ecstein-Fraisse, Evelyne
    Ura, Takashi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2016, 46 (11) : 1000 - 1007
  • [2] PHASE I STUDY OF OMBRABULIN, A VASCULAR DISRUPTING AGENT (VDA), ADMINISTERED EVERY 3 WEEKS TO JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS
    Kurata, T.
    Murakami, H.
    Fujisaka, Y.
    Kiyota, H.
    Hayashi, H.
    Tanaka, K.
    Nakagawa, K.
    Onozawa, Y.
    Watanabe, J.
    Yamamoto, N.
    Aoyama, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 110 - 110
  • [3] PHASE I STUDY OF OMBRABULIN IN COMBINATION WITH PACLITAXEL plus CARBOPLATIN ADMINISTERED EVERY 3 WEEKS TO JAPANESE PATIENTS
    Matsumoto, K.
    Fujiwara, K.
    Tanioka, M.
    Onoe, T.
    Negoro, S.
    Shimada, K.
    Saji, S.
    Sasaki, Y.
    Noguchi, K.
    ANNALS OF ONCOLOGY, 2013, 24
  • [4] Phase 1 study of ombrabulin in combination with docetaxel and cisplatin in Japanese patients with advanced solid tumors
    Nishio, Makoto
    Satouchi, Miyako
    Horiike, Atsushi
    Horio, Yoshitsugu
    Sunaga, Yoshinori
    Ecstein-Fraisse, Evelyne
    Hida, Toyoaki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2018, 48 (04) : 322 - 328
  • [5] Phase I study of ombrabulin in combination with paclitaxel and carboplatin in Japanese patients with advanced solid tumors
    Matsumoto, Koji
    Sunaga, Yoshinori
    Ecstein-Fraisse, Evelyne
    Fujiwara, Keiichi
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (04) : 586 - 593
  • [6] Phase I And pharmacokinetic study of irofulven (IROF) in combination with cisplatin (CDDP), given every 2 weeks, in patients (pts) with advanced solid tumors.
    Hilgers, W
    Alexandre, J
    Tourani, JM
    Misset, JL
    Goldwasser, F
    Bourgeois, H
    Faivre, S
    Kahatt, C
    Cvitkovic, E
    Weems, G
    Raymond, E
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6080S - 6080S
  • [7] Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours
    X Chen
    A M Oza
    Z Kusenda
    Q-L Yi
    D Kochman
    M J Moore
    A J Davis
    L L Siu
    British Journal of Cancer, 2003, 89 : 617 - 624
  • [8] Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours
    Chen, X
    Oza, AM
    Kusenda, Z
    Yi, QL
    Kochman, D
    Moore, MJ
    Davis, AJ
    Siu, LL
    BRITISH JOURNAL OF CANCER, 2003, 89 (04) : 617 - 624
  • [9] Phase I dose-escalation study of brostallicin in combination with cisplatin (cDDP) in patients with advanced solid tumors
    Lorusso, D.
    Fornari, G.
    Caponigro, F.
    Quirino, M.
    Merlano, M.
    Airoldi, M.
    Schena, M.
    Jannuzzo, M. G.
    Crippa, S.
    Scambia, G.
    EJC SUPPLEMENTS, 2007, 5 (04): : 111 - 112
  • [10] Phase I trial of tirapazamine in combination with cisplatin in a single dose every 3 weeks in patients with solid tumors
    Johnson, CA
    Kilpatrick, D
    vonRoemeling, R
    Langer, C
    Graham, MA
    Greenslade, D
    Kennedy, G
    Keenan, E
    ODwyer, PJ
    JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) : 773 - 780
12345